Lataa...
Bevacizumab for progressive glioblastoma multiforme: a case of treading the tightrope
Until March 2013, Bevacizumab had been funded through the National Cancer Drugs Fund (CDF) for the treatment of recurrent/progressive Glioblastoma multiforme (GBM). Although the CDF concluded at the time that there was insufficient evidence around the effectiveness of the Bevacizumab on overall surv...
Tallennettuna:
| Julkaisussa: | Neuro Oncol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5791690/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox238.094 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|